1. Home
  2. BRLT vs RNTX Comparison

BRLT vs RNTX Comparison

Compare BRLT & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brilliant Earth Group Inc.

BRLT

Brilliant Earth Group Inc.

HOLD

Current Price

$1.28

Market Cap

36.6M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.35

Market Cap

30.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRLT
RNTX
Founded
2005
2001
Country
United States
United States
Employees
N/A
11
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.6M
30.0M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BRLT
RNTX
Price
$1.28
$1.35
Analyst Decision
Hold
Buy
Analyst Count
4
2
Target Price
$1.70
$10.00
AVG Volume (30 Days)
92.5K
85.7K
Earning Date
06-16-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$422,161,000.00
N/A
Revenue This Year
$6.37
N/A
Revenue Next Year
$6.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.23
$1.02
52 Week High
$3.10
$2.22

Technical Indicators

Market Signals
Indicator
BRLT
RNTX
Relative Strength Index (RSI) 35.46 65.75
Support Level N/A $1.34
Resistance Level $1.66 $1.57
Average True Range (ATR) 0.10 0.11
MACD -0.02 0.02
Stochastic Oscillator 11.36 96.77

Price Performance

Historical Comparison
BRLT
RNTX

About BRLT Brilliant Earth Group Inc.

Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: